The role of estrogen receptor β (ERβ) in malignant diseases-A new potential target for antiproliferative drugs in prevention and treatment of cancer

Margaret Warner, Jan Åke Gustafsson

    Research output: Contribution to journalArticlepeer-review

    72 Scopus citations

    Abstract

    The discovery of ERβ in the middle of the 1990s represents a paradigm shift in our understanding of estrogen signaling. It has turned out that estrogen action is not mediated by one receptor, ERα, but by two balancing factors, ERα and ERβ, which are often antagonistic to one another. Excitingly, ERβ has been shown to be widespread in the body and to be involved in a multitude of physiological and pathophysiological events. This has led to a strong interest of the pharmaceutical industry to target ERβ by drugs against various diseases. In this review, focus is on the role of ERβ in malignant diseases where the anti proliferative activity of ERβ gives hope of new therapeutic approaches.

    Original languageEnglish (US)
    Pages (from-to)63-66
    Number of pages4
    JournalBiochemical and Biophysical Research Communications
    Volume396
    Issue number1
    DOIs
    StatePublished - May 21 2010

    Keywords

    • Antiproliferative
    • Cancer
    • Drug
    • Gene expression
    • Nuclear receptor
    • Pharmaceutical
    • Transcription

    ASJC Scopus subject areas

    • Biochemistry
    • Biophysics
    • Cell Biology
    • Molecular Biology

    Fingerprint

    Dive into the research topics of 'The role of estrogen receptor β (ERβ) in malignant diseases-A new potential target for antiproliferative drugs in prevention and treatment of cancer'. Together they form a unique fingerprint.

    Cite this